The impact of myocardial viability on the clinical outcome of cardiac resynchronization therapy
- PMID: 18803571
- DOI: 10.1111/j.1540-8167.2008.01294.x
The impact of myocardial viability on the clinical outcome of cardiac resynchronization therapy
Abstract
Introduction: Around 30% of patients do not respond to cardiac resynchronization therapy (CRT). Nonischemic cardiomyopathy has been identified as an independent predictor of response to CRT, probably due to the absence of compact scar.
Methods and results: The relationship between cardiac scar, ischemia, and hibernation (both at the left-ventricular pacing site and as a total burden) and response to CRT was studied in patients with ischemic cardiomyopathy using the perfusion-viability positron emission tomography (PET) test. Sixty-six patients with ischemic cardiomyopathy and traditional criteria for CRT were included. All patients underwent PET scan prior to CRT. Using PET, the amount and location of scarred, ischemic, and hibernating myocardium were characterized. No revascularization was indicated. Responders were defined by an improvement of left-ventricular ejection fraction (LVEF) >or= 5% and/or New York Heart Association (NYHA) class >or= 1 degree. During a mean follow-up of 26.2 +/- 22.2 months, there was a significant improvement in NYHA class and reverse remodeling in patients with the LV lead inserted remotely from the scar. However, reverse remodeling of a similar degree was present also in patients with extensive scarring including the lateral wall. The presence of ischemia, hibernation, or nontransmural scar at the pacing-site did not significantly modify the outcome of CRT as compared with viable myocardium. There were only 38% of CRT-nonresponders. Neither the extent of scar, ischemia, hibernation, or viability predicted outcome or mortality. Twenty patients died during the follow-up, one patient underwent heart transplant.
Conclusions: At follow-up, response to CRT is observed regardless of the presence of extensive scarring. Left ventricular (LV) pacing at sites with ischemia, hibernation, or nontransmural scar does not appear to modify the effect of CRT as compared to viable tissue.
Similar articles
-
Cardiac resynchronization therapy in patients with systolic left ventricular dysfunction and symptoms of mild heart failure secondary to ischemic or nonischemic cardiomyopathy.Am J Cardiol. 2006 Jul 15;98(2):230-5. doi: 10.1016/j.amjcard.2006.01.080. Epub 2006 May 19. Am J Cardiol. 2006. PMID: 16828599
-
Clinical predictors of marked improvement in left ventricular performance after cardiac resynchronization therapy in patients with chronic heart failure.Am Heart J. 2006 Feb;151(2):477.e1-477.e6. doi: 10.1016/j.ahj.2005.08.008. Am Heart J. 2006. PMID: 16442917
-
Magnetic resonance imaging is superior to cardiac scintigraphy to identify nonresponders to cardiac resynchronization therapy.Pacing Clin Electrophysiol. 2009 Mar;32 Suppl 1:S57-62. doi: 10.1111/j.1540-8159.2008.02227.x. Pacing Clin Electrophysiol. 2009. PMID: 19250113 Clinical Trial.
-
Assessment of myocardial viability.Curr Opin Cardiol. 1997 Sep;12(5):459-67. Curr Opin Cardiol. 1997. PMID: 9352173 Review.
-
Assessment of myocardial viability in chronic ischemic heart disease: current status.Q J Nucl Med Mol Imaging. 2005 Mar;49(1):81-96. Q J Nucl Med Mol Imaging. 2005. PMID: 15724138 Review.
Cited by
-
The value of non-invasive myocardial work indices derived from left ventricular pressure-strain loops in predicting the response to cardiac resynchronization therapy.Quant Imaging Med Surg. 2021 Apr;11(4):1406-1420. doi: 10.21037/qims-20-754. Quant Imaging Med Surg. 2021. PMID: 33816178 Free PMC article.
-
The amount of viable and dyssynchronous myocardium is associated with response to cardiac resynchronization therapy: initial clinical results using multiparametric ECG-gated [18F]FDG PET.Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1876-83. doi: 10.1007/s00259-013-2516-6. Epub 2013 Aug 1. Eur J Nucl Med Mol Imaging. 2013. PMID: 23903666
-
Left ventricular systolic and diastolic dyssynchrony to improve cardiac resynchronization therapy response in heart failure patients with dilated cardiomyopathy.J Nucl Cardiol. 2021 Jun;28(3):1023-1036. doi: 10.1007/s12350-020-02132-1. Epub 2020 May 13. J Nucl Cardiol. 2021. PMID: 32405991 Free PMC article.
-
Evidence of scar tissue: contra-indication to cardiac resynchronization therapy?Int J Cardiovasc Imaging. 2011 Jan;27(1):59-63. doi: 10.1007/s10554-010-9664-6. Epub 2010 Jul 8. Int J Cardiovasc Imaging. 2011. PMID: 20614190 Free PMC article. No abstract available.
-
Epicardial Adipose Tissue Measured From Computed Tomography Predicts Cardiac Resynchronization Therapy Response in Patients With Non-ischemic Systolic Heart Failure.Front Cardiovasc Med. 2021 Oct 28;8:678467. doi: 10.3389/fcvm.2021.678467. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34778385 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials